Abstract
β-secretase (BACE1) inhibition has emerged as a most promising target for the treatment of Alzheimer’s disease. In the present study an in silico approach has been successfully utilized for the development of diverse classification models for the prediction of BACE1 inhibitory activity using a dataset consisting of 42 differently substituted aminohydantoin analogues. Classification tree (CT), moving average analysis (MAA) and random forest (RF) were utilized for development of models. Two out of three MDs identified by CT as the most important were the detour cum distance matrix based topological descriptors proposed in part-I of the manuscript.
Various models resulted in the prediction of BACE1 inhibitory activity with an overall accuracy of >92%. Overall accuracy, non-error rate, intercorrelation analysis, specificity, sensitivity and Mathew’s correlation coefficient (MCC) were utilized to determine statistical significance of the said models. Proposed models provide an immense potential for furnishing lead molecules so as to unfold potent BACE1 inhibitors for the treatment of Alzheimer’s disease.
Keywords: Aminohydantoins, BACE1 inhibitors, Classification/decision tree, Molecular descriptors, Random forest, Relative distance sum/product descriptors.
Letters in Drug Design & Discovery
Title:Detour Cum Distance Matrix Based Topological Descriptors for QSAR/QSPR Part-II: Application in Drug Discovery Process
Volume: 11 Issue: 7
Author(s): Monika Gupta and Anil K. Madan
Affiliation:
Keywords: Aminohydantoins, BACE1 inhibitors, Classification/decision tree, Molecular descriptors, Random forest, Relative distance sum/product descriptors.
Abstract: β-secretase (BACE1) inhibition has emerged as a most promising target for the treatment of Alzheimer’s disease. In the present study an in silico approach has been successfully utilized for the development of diverse classification models for the prediction of BACE1 inhibitory activity using a dataset consisting of 42 differently substituted aminohydantoin analogues. Classification tree (CT), moving average analysis (MAA) and random forest (RF) were utilized for development of models. Two out of three MDs identified by CT as the most important were the detour cum distance matrix based topological descriptors proposed in part-I of the manuscript.
Various models resulted in the prediction of BACE1 inhibitory activity with an overall accuracy of >92%. Overall accuracy, non-error rate, intercorrelation analysis, specificity, sensitivity and Mathew’s correlation coefficient (MCC) were utilized to determine statistical significance of the said models. Proposed models provide an immense potential for furnishing lead molecules so as to unfold potent BACE1 inhibitors for the treatment of Alzheimer’s disease.
Export Options
About this article
Cite this article as:
Gupta Monika and Madan K. Anil, Detour Cum Distance Matrix Based Topological Descriptors for QSAR/QSPR Part-II: Application in Drug Discovery Process, Letters in Drug Design & Discovery 2014; 11 (7) . https://dx.doi.org/10.2174/1570180811666140401182931
DOI https://dx.doi.org/10.2174/1570180811666140401182931 |
Print ISSN 1570-1808 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-628X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Proposing a “Lipemic Index” As a Nutritional and Research Tool
Current Vascular Pharmacology Hypothalamic Insulin-Sensitizing Effect of Exenatide in Dietary Induced Rat Model of Obesity
Current Drug Therapy Cardiovascular Effects of Antiretroviral Drugs: Clinical Review
Cardiovascular & Hematological Disorders-Drug Targets Antiplatelet Therapies: Platelet GPIIb / IIIa Antagonists and Beyond
Current Pharmaceutical Design Antioxidant Effect of Flavonoids Present in Euterpe oleracea Martius and Neurodegenerative Diseases: A Literature Review
Central Nervous System Agents in Medicinal Chemistry Adenosine A2A Receptor Antagonists and Parkinsons Disease: State of the Art and Future Directions
Current Pharmaceutical Design Detection and Transport Mechanisms of Circulating microRNAs in Neurological, Cardiac and Kidney Diseases
Current Medicinal Chemistry Recent Advances in Nanotherapeutic Interventions for the Treatment of Alzheimer’s Disease
Current Pharmaceutical Design Treatment of Hypertensive Left Ventricular Hypertrophy
Current Pharmaceutical Design Acetylcholinesterase (AChE) - Amyloid-β-Peptide Complexes in Alzheimers Disease. The Wnt Signaling Pathway
Current Alzheimer Research Melatonin as Antioxidant Under Pathological Processes
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Assessment of apolipoprotein E genotype for β-amyloid status prediction
Current Alzheimer Research Estrogen Receptors as Therapeutic Targets in Breast Cancer
Current Topics in Medicinal Chemistry New Insight into the Mechanisms of <i>Ginkgo Biloba</i> Extract in Vascular Aging Prevention
Current Vascular Pharmacology Probing Cerebrovascular Alterations in Alzheimers Disease Using MRI: From Transgenic Models to Patients
Current Medical Imaging Heat Shock Proteins: Therapeutic Drug Targets for Chronic Neurodegeneration?
Current Pharmaceutical Biotechnology Synthesis and In Vitro Evaluation of New Tacrine Derivates-Bis-Alkylene Linked 7-MEOTA
Letters in Organic Chemistry Early Ischemic Blood Brain Barrier Damage: A Potential Indicator for Hemorrhagic Transformation Following Tissue Plasminogen Activator (tPA) Thrombolysis?
Current Neurovascular Research Nanomaterials for Neurology: State-of-the-Art
CNS & Neurological Disorders - Drug Targets Cannabinoids and Neuro-Inflammation: Regulation of Brain Immune Response
Recent Patents on CNS Drug Discovery (Discontinued)